anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Motivational eating behavior traits (i.e. eating motivations and intuitive eating) have an important role in body weight regulation, as do food reward processes. Their associations might help explain different responses to food stimulus in the current environment but have never been explored. This study's primary goal was to investigate food reward associations with eating motivations, intuitive eating dimensions and body mass index in former Portuguese elite athletes with overweight/obesity. As a first step, a cultural adaptation of the Leeds Food Preference Questionnaire (LFPQ) was created and validated in an online-surveyed Portuguese sample.
RESULTS: Step 1: Analysis from an online survey (N = 348; 69.8% female) conducted to validate the food images from the cultural adaptation of the LFPQ showed that most food images were properly recognized in terms of their fat and sweet content by the Portuguese population, except for some savory items. Step 2: Regarding our primary analysis in 94 former elite athletes with overweight/obesity, self-determined motivations to regulate eating and (to a lower extent) more body-food congruent choices (both markers for healthier eating behaviors) were associated with more favorable food reward outcomes, as opposed to non-self-determined motivations. Less emotional (more intuitive) eaters presented higher implicit wanting for low-fat sweet foods compared to more emotional eaters.
CONCLUSION: These findings suggest LFPQ usefulness to evaluate food preferences and detect relevant associations between food reward and motivational eating behavior traits in former elite athletes with overweight/obesity. Health professionals are encouraged to create need-supportive environments that foster self-determined motivations and help individuals make healthier food choices. © 2023 Society of Chemical Industry.
A system, method, and computer-readable medium are disclosed for auditory adaptive wellness. A user's sensitivity to noise and frequency is calibrated. Thresholds are set for three use cases of dosage fatigue, background cumulative frequency and general frequency fatigue. Audio cumulation rates of peripherals for is determined for the three use cases. Cumulative dosage exposure (CDE), cumulative background exposure (CBE) and cumulative frequency exposure (CFE) are calculated. Warnings and recommendations are provided when CDE exceeds the threshold for dosage fatigue, CBE exceeds the threshold for background cumulative frequency fatigue, and CFE exceeds the threshold for general frequency fatigue.
Receptors controlling the cross-presentation of tumor antigens by macrophage subsets in cancer tissues are poorly explored. Here, we show that TIM4+ large peritoneal macrophages efficiently capture and cross-present tumor-associated antigens at early stages of peritoneal infiltration by ovarian cancer cells. The phosphatidylserine (PS) receptor TIM4 promotes maximal uptake of dead cells or PS-coated artificial targets and triggers inflammatory and metabolic gene programs in combination with cytoskeletal remodeling and upregulation of transcriptional signatures related to antigen processing. At the cellular level, TIM4-mediated engulfment induces nucleation of F-actin around nascent phagosomes, delaying the recruitment of vacuolar ATPase, acidification, and cargo degradation. In vivo, TIM4 deletion blunts induction of early anti-tumoral effector CD8 T cells and accelerates the progression of ovarian tumors. We conclude that TIM4-mediated uptake drives the formation of specialized phagosomes that prolong the integrity of ingested antigens and facilitate cross-presentation, contributing to immune surveillance of the peritoneum.
Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
Ototoxicity with use of ZEMDRI

Ototoxicity, manifested as hearing loss, tinnitus, and/or vertigo, has been reported with ZEMDRI. Symptoms of aminoglycoside-associated ototoxicity may be irreversible and may not become evident until after completion of therapy.

Regarding the incidence of adverse reactions associated with cochlear or vestibular function, in Trial 1, there was one case of reversible hypoacusis (1/303;0.3%) in ZEMDRI-treated patients and one case of tinnitus (1/301;0.3%) in meropenem-treated patients [see Adverse Reactions (6.1)]. In Trial 2, one case each of irreversible tinnitus and reversible vertigo was reported in ZEMDRI-treated patients, and one case of an abnormal audiogram occurred in a levofloxacin-treated patient [see Adverse Reactions (6.1)].

Aminoglycoside-associated ototoxicity has been observed primarily in patients with a family history of hearing loss (excluding age-related hearing loss), patients with renal impairment, and in patients receiving higher doses and/or for longer periods than recommended. In Trial 1 and Trial 2, patients with a history of hearing loss, with the exception of age-related hearing loss, were excluded. The benefit-risk of ZEMDRI therapy should be considered in these patients.

Risk of Ototoxicity Due to Mitochondrial DNA Variants

Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A>G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.
The present invention discloses a workflow oriented multi-screen healthcare information management system. The present invention allows the user to simultaneously access, display, and manipulate various healthcare information that are logically related on multiple screens without having to jump around or entering and exiting various screens. In particular, the present invention provides a first screen for managing information for a first point in the healthcare workflow and a second screen for managing information for a second point in the healthcare workflow, where the first screen and the second screen has a logical relation in the healthcare workflow. Various tasks in the healthcare workflow can be streamlined utilizing the system of the present invention. Specifically, the first and second screens can conveniently display complete patient history. The physician can write orders while viewing labs and medications. An X-ray report and problem list will be visible at the same time while the physician is writing SOAP notes. Writing discharge orders is simplified since all prescribed medications can be automatically printed. In addition, physician's orders are transmitted and processed automatically. As the result, physicians will benefit from improved efficiency, less time spent on charting, and more time spent with the patients. Errors will be reduced significantly throughout the entire healthcare process or workflow.
PURPOSE: A pharmaceutical and health supplementary food composition containing a concentrate of ground water is provided. The concentrate of ground water is obtained by concentrating ground water by itself or after the demineralization and non-toxic and can be used as a drug or health supplementary beverage for preventing or treating cancer. CONSTITUTION: The pharmaceutical and health supplementary food composition contains 0.01 to 80% by weight of a concentrate of ground water. The ground water is pumped out of the ground of 700 to 1,000m and contains inorganic components selected from Na, Ca, Mg, K, Zn and the like and metal ions selected from Fe, Mn, St and the like in large quantities. The composition has a daily dose level of 0.01 to 10g per body weight. The hair growing agent composition is a tablet, capsule, solution, dispersion or syrup. For an example, 100mg powder of ground water concentrate is mixed with 3.0mg sodium metabisulphite, 0.8mg methyl paraben, 0.1mg propyl paraben and a suitable amount of sterilized distilled water to give a final volume of 2ml.
One or more devices that provides an immersive cerebral salubrity retention and selection package (ICSRSP) to potential new patients (PNPs) comprising customized cerebral salubrity care personnel with available personal time periods to improve their cerebral salubrity. An ICSRSP determines whether a PNP qualifies for a cerebral health immersion program (CHIP). The ICSRSP generates a set of interrogatives based on data and data sets (used for a determination) that are not included in initially collected data regarding the PNP. The PNP's acceptance into the ICSRSP is based on an assessment of the PNP data and PNP-provided responses to the interrogatives. If the PNP is selected for the CHIP, an option is provided to the PNP to enroll in the CHIP to become a patient. If additional information is needed to complete an acceptance process for the CHIP, a user interface is provided enabling the PNP to provide data for process completion.
Acute Treatment of Manic and Mixed Episodes

Adults: The recommended starting dose in adults is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. ABILIFY can be given without regard to meals. The recommended target dose of ABILIFY is 15 mg/day, as monotherapy or as adjunctive therapy with lithium or valproate. The dose may be increased to 30 mg/day based on clinical response. The safety of doses above 30 mg/day has not been evaluated in clinical trials.

Pediatrics: The recommended starting dose in pediatric patients (10 to 17 years) as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. Recommended dosing as adjunctive therapy to lithium or valproate is the same. Subsequent dose increases, if needed, should be administered in 5 mg/day increments. ABILIFY can be given without regard to meals . [see CLINICAL STUDIES ] (14.2)

Maintenance Treatment

The recommended dose for maintenance treatment, whether as monotherapy or as adjunctive therapy, is the same dose needed to stabilize patients during acute treatment, both for adult and pediatric patients. Patients should be periodically reassessed to determine the continued need for maintenance treatment [see CLINICAL STUDIES ]. (14.2)
PROBLEM TO BE SOLVED: To obtain an adhesive compsn. which has an improved polymerizability at an adhesion interface and strongly adheres to teeth by compounding a photopolymn. initiator, an acidic compd., an aryl borate compd., and a polymerizable (meth) acrylate monomer. SOLUTION: A photopolymn. initiator (A) which generates free radicals on exposure to ultraviolet or visible rays can be used without any specific limitation, an esp. pref. one being camphorquinone. Normal inorg. and org. acids can be used as the acidic compd. (B) without being specifically limited. though the use of an acid-group-contg. polymerizable (meth)acrylate monomer is favorable for improving adhesion to teeth and for inhibiting the dissolution of low-molecular compds. from a cured article. A compd. of the formula (wherein R3 to R7 are each H, alkyl or the like; and L<+> is a metal ion or an org. base ion) is an example of the aryl borate compd. (C). Any known polymerizable (meth)acrylate monomer can be used without being specifically limited. The compsn. may further contain a filler and water.
The capsules are pref. H2O-sol. and prepd. from gelatine opt. with polyethylene oxides and/or high mol.wt. carbohydrates, are partially filled with (a) a therapeutic agent, (b) an effervescent mixt i.e. a carbonate or bicarbonate and an acid, and (c) a foaming agent, pref. a non-ionogenic surfactant. Prior to insertion, water is introduced into the capsules, to initiate the reaction and so that the mucous membranes do not suffer the imitation which the use of a dry compsn. would cause by dehydration.
The invention comprises the compounds of formulae <FORM:0969418/C1/1> and their salts; and their preparation by reaction of 2-chloroethyl-isocyanate with 2-amino -5-nitro-thiazole forming the chloroethyl compound which may be hydrolysed forming the hydroxyethyl compound.  Reference has been directed by the Comptroller to Specification 877,106.ALSO:Pharmaceutical (including veterinary) preparations, animal feedstuffs and feedstuffs additives comprise the compound of formula <FORM:0969418/A5-A6/1> or a salt thereof in admixture or conjuction with, respectively, pharmaceutical excipients, animal foods and edible carriers. Solid (tablets, dragees, capsules) and liquid (solutions, suspensions or emulsions) pharmaceutical preparations are mentioned for oral and parenteral administration.  For animal feeding, solid mixtures and solutions and dispersions are mentioned; other ingredients specified include antibiotics (e.g. tetracycline, chlortetracycline), hormone-like compounds (e.g. diethylstilbestrol, hexestrol) and growth-promoting factors (e.g. Apocynace  alkaloids) as well as dietary supplements (including vitamins).  The compounds act against parasites, particularly protozoa and coccidiosis in poultry.  Reference has been directed by the Comptroller to Specification 877,106.
Capsules not containing the active ingredient B. longum ES1. One capsule taken before and after consuming 2 slices of bread for 7 days.
Intention-driven assistive functional electrical stimulation provided during approximately 1 hour of task-oriented therapy. Sessions will be scheduled 3 days per week for 8 weeks.
RNA binding motif protein X-linked (RBMX) encodes the heterogeneous nuclear ribonucleoprotein G (hnRNP G) that regulates splicing, sister chromatid cohesion and genome stability. RBMX knock down experiments in various model organisms highlight the gene's importance for brain development. Deletion of the RGG/RG motif in hnRNP G has previously been associated with Shashi syndrome, however involvement of other hnRNP G domains in intellectual disability remain unknown. In the current study, we present the underlying genetic and molecular cause of Gustavson syndrome. Gustavson syndrome was first reported in 1993 in a large Swedish five-generation family presented with profound X-linked intellectual disability and an early death. Extensive genomic analyses of the family revealed hemizygosity for a novel in-frame deletion in RBMX in affected individuals (NM_002139.4; c.484_486del, p.(Pro162del)). Carrier females were asymptomatic and presented with skewed X-chromosome inactivation, indicating silencing of the pathogenic allele. Affected individuals presented minor phenotypic overlap with Shashi syndrome, indicating a different disease-causing mechanism. Investigation of the variant effect in a neuronal cell line (SH-SY5Y) revealed differentially expressed genes enriched for transcription factors involved in RNA polymerase II transcription. Prediction tools and a fluorescence polarization assay imply a novel SH3-binding motif of hnRNP G, and potentially a reduced affinity to SH3 domains caused by the deletion. In conclusion, we present a novel in-frame deletion in RBMX segregating with Gustavson syndrome, leading to disturbed RNA polymerase II transcription, and potentially reduced SH3 binding. The results indicate that disruption of different protein domains affects the severity of RBMX-associated intellectual disabilities.
BACKGROUND: Hemodialysis is an important health problem that negatively affects psychosocial status and support systems. Through practices such as mandala coloring, individuals transfer the unknowns they experience to the outside and make them visible. This study was conducted to examine the effects of mandala coloring on fatigue, psychological well-being, and factors associate with coping with stress in patients receiving hemodialysis treatment.
METHODS: The design was a prospective, parallel-group controlled trial. The study was conducted in the dialysis unit of a university hospital in eastern Turkey between April 4 and October 31, 2022, with a total of 60 patients, 30 in the intervention group, and 30 in the control group. The patients in the intervention group colored mandala once a week for 2 h, for a total of 8 weeks. The data were collected face-to-face using a patient information form, a Fatigue Severity Scale, a Psychological Well-Being Scale, and a Ways of Coping Questionnaire.
RESULTS: There were improvements in fatigue severity and psychological well-being over the 8-week study period in both the intervention and control groups. Scores were similar at baseline in the control and intervention groups, but better in the intervention groups compared to controls at 4 and 8 weeks for both metrics (p < 0001). Five factors from the Ways of Coping Questionnaire (self-confident approach, optimistic approach, seeking social support, helpless approach, and submissive approach) each improved during the 8-week period in the intervention group (p < 0.001). Three of these five factors improved in the control group as well. Scores for each of the five coping factors were better in the intervention group compared to controls at 4 and 8 weeks (p < 0.001).
CONCLUSION: Mandala coloring improved fatigue and psychological well-being and was associated with improved patient coping strategies.
Duloxetine is excreted into the milk of lactating women. The estimated daily infant dose on a mg/kg basis is approximately 0.14% of the maternal dose. Because the safety of duloxetine in infants is not known, nursing while on duloxetine is not recommended. However, if the physician determines that the benefit of duloxetine therapy for the mother outweighs any potential risk to the infant, no dosage adjustment is required as lactation did not influence duloxetine pharmacokinetics. 

The disposition of duloxetine was studied in 6 lactating women who were at least 12 weeks postpartum. Duloxetine 40 mg twice daily was given for 3.5 days. Like many other drugs, duloxetine is detected in breast milk, and steady state concentrations in breast milk are about one-fourth those in plasma. The amount of duloxetine in breast milk is approximately 7 mcg/day while on 40 mg BID dosing. The excretion of duloxetine metabolites into breast milk was not examined. Because the safety of duloxetine in infants is not known, nursing while on duloxetine is not recommended [see Dosage and Administration (2.3)].
Corn peptide (CP) is a short, naturally occurring, and physiologically active peptide generated from corn-protease-catalyzed hydrolysis. CP plays a role in preventing obesity-related disorders, but its impact on reducing inflammation is unknown. Hence, this study examined the possible protective effects of corn peptide powder (CPP) against the harmful effects of lipopolysaccharide (LPS), with a particular emphasis on reducing oxidative damage and inflammation in adipocytes. Hence, mature 3T3-L1 adipocytes underwent exposure to 10 ng/mL LPS, with or without CPP (10 and 20 μg/mL). LPS stimulation increased reactive oxygen species and superoxide anion generation. However, this effect was reduced in a dose-dependent manner by pretreatment with CPP. CPP treatment elevated the mRNA expressions of the antioxidant enzymes manganese superoxide dismutase (mnSOD) and glutathione peroxidase 1 (Gpx1) while reducing the mRNA expressions of the cytosolic reactive oxygen species indicators p40 and p67 (NADPH oxidase 2). In addition, CPP inhibited the monocyte chemoattractant protein-1, tumor necrosis factor-alpha, Toll-like receptor 4, and nuclear factor kappa B mRNA expressions induced by LPS. These findings demonstrate that CPP may ameliorate adipocyte dysfunction by suppressing oxidative damage and inflammatory responses through a new mechanism known as Toll-like receptor 4/nuclear factor kappa B-mediated signaling.
* TYENNE for subcutaneous injection is not intended for intravenous drip infusion. 
  * Assess suitability of patient for subcutaneous home use and instruct patients to inform a healthcare professional before administering the next dose if they experience any symptoms of allergic reaction. Patients should seek immediate medical attention if they develop symptoms of serious allergic reactions. TYENNE subcutaneous injection is intended for use under the guidance of a healthcare practitioner. After proper training in subcutaneous injection technique, a patient may self-inject TYENNE or the patient's caregiver may administer TYENNE if a healthcare practitioner determines that it is appropriate. PJIA and SJIA patients may self-inject with the TYENNE prefilled syringe or autoinjector, or the patient's caregiver may administer TYENNE if both the healthcare practitioner and the parent/legal guardian determine it is appropriate [see Use in Specific Populations (8.4)].   
Patients, or patient caregivers, should be instructed to follow the directions provided in the Instructions for Use (IFU) for additional details on medication administration. 
  * Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use TYENNE prefilled syringes (PFS) or prefilled autoinjectors exhibiting particulate matter, cloudiness, or discoloration. TYENNE for subcutaneous administration should be clear and colorless to pale yellow. Do not use if any part of the PFS or autoinjector appears to be damaged. 
  * Patients using TYENNE for subcutaneous administration should be instructed to inject the full amount in the syringe (0.9 mL) or full amount in the autoinjector (0.9 mL), which provides 162 mg of TYENNE, according to the directions provided in the IFU. 
  * Injection sites should be rotated with each injection and should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.
An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
The most common agent of lower respiratory infections in early childhood is respiratory syncytial virus (RSV). Because there is no clear mechanism of the infection, the effective methods of therapy are not easy to develop. FIP-fve and FIP-gts are a family of immunomodulatory proteins isolated from Flammulina velutipes and Ganoderma tsugae, respectively. The molecular weight of FIPs is about 13 kDa. These family proteins stimulated the production of IFN- γ and reduced the allergic inflammation in human PBMCs. In this claim, we detect the quantity of RSV on HEp-2 cells by RT-PCR, plaque assay, Immunofluorescence assay and ELISA after FIP-fve treatment and find that FIP-fve may suppress the infection of RSV. In the claim, we detected the proteins of phospho-NF- κ B and phosphor-I κ B α with Western blotting and observed the translocation of NF- κ B in A549 cells. These results demonstrate that FIP-fve reduce the phosphorylation of NF- κ B and I κ B α and the translocation of NF- κ B. Furthermore, the inflammatory cytokines are decreased in HEp-2 cells with FIP-fve treatment. In vivo, oral FIP-fve and FIP-gts could alleviate on RSV-induced airway inflammation. They are developed to therapeutic agents for viral airway disease.